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Heterozygous mice for TGF-bIIR gene are resistant to the
progression of streptozotocin-induced diabetic nephropathy
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Heterozygous mice for TGF-bIIR gene are resistant to the pro-
gression of streptozotocin-induced diabetic nephropathy.
Background. Transforming growth factor-b (TGF-b) recep-
tor complex and its downstream Smad signaling intermediates
constitute an extracellular matrix (ECM) accumulation path-
way.
Methods. In the present study, we examined whether de-
creased expression of the TGF-b type II receptor (TGF-bIIR)
in TGF-bIIR gene heterozygous (TGF-bIIR+/−) (HT) mice
could inhibit the Smad signaling pathway and subsequent pro-
gression of renal lesions when streptozotocin (STZ) diabetes is
induced.
Results. At the end of the 28-week experiment after STZ
injections, wild-type diabetic mice showed severe glomerular
hypertrophy and mesangial matrix accumulation occasionally
featuring nodular glomerulosclerosis. In contrast, mean
glomerular area and mesangial volume density were signifi-
cantly decreased in the HT diabetic mice as compared with
the wild-type diabetic mice. Immunostaining for phosphory-
lated Smad2/Smad3 and TGF-bIIR in the glomerular cells was
also significantly reduced in the HT diabetic mice. Southwest-
ern histochemistry using digoxigenin-labeled CAGA sequence
probes showed that localization of labeled probes to the nuclei
of glomerular cells in the HT diabetic mice was significantly less
frequent than that in the wild-type diabetic animals. Northern
blot analysis showed that a1(IV) collagen mRNA levels were
significantly reduced in the kidney tissue of HT diabetic mice
as compared with the wild-type diabetic mice.
Conclusion. These results suggest that decreased expression
of TGF-bIIR in the HT diabetic mice can inhibit the progres-
sion of diabetic renal injury by inhibiting the downstream Smad
signaling pathway and subsequent ECM gene expression. Thus,
TGF-bIIR appears to play an important role in the progres-
sion of diabetic nephropathy by mediating intracellular Smad
signaling.
Excessive amounts of extracellular matrix (ECM),
such as a1(IV) collagen, fibronectin, or plasminogen ac-
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tivator inhibitor-1 (PAI-1), accumulate in the glomeruli
of rodents or patients with diabetic nephropathy [1–4].
Transforming growth factor-b (TGF-b) is a key regulator
of ECM, and diabetes results in the activation of the renal
TGF-b system.
TGF-b exerts its effects through an interaction with the
TGF-b type II receptor (TGF-bIIR) and the type I recep-
tor [5, 6]. Upon TGF-b binding, the TGF-bIIR activates
the TGF-b type I receptor kinase, which then phospho-
rylates the Smad2 and Smad3 [7, 8]. The phosphorylated
Smads form heteromeric complexes with Smad4, which
translocate to the nucleus. In the nucleus, the Smad3-
Smad4 complex can activate transcription through di-
rect binding to certain DNA sequences, such as the
GTCTAGAC-called Smad binding element (SBE) [9] or
the AG(C/A)CAGACAC-called CAGA box [10]. Hu-
man PAI-1 and a2(I) collagen gene promoters contain
CAGA boxes [10–13].
TGF-bIIR is up-regulated in mesangial cells cultured
under high glucose conditions [14, 15]. Also, TGF-bIIR
expression is increased in the glomeruli of experimental
models of diabetes, such as the streptozotocin (STZ) di-
abetic mouse or the spontaneously diabetic db/db mouse
[16–19]. However, the role of TGF-bIIR in the progres-
sion of diabetic nephropathy is not yet clearly defined.
TGF-bIIR is essential for hematopoiesis and vasculo-
genesis in the yolk sac and, therefore, TGF-bIIR gene
knockout mice die at embryonic day [20]. Im et al [21]
observed that the levels of TGF-bIIR mRNA and pro-
tein in the liver tissues of TGF-bIIR gene heterozy-
gous (TGF-bIIR+/−) (HT) mice were decreased with the
gene-dosage effect. Thus, using HT mice could be a use-
ful approach in studying the role of TGF-bIIR in the
progression of diabetic nephropathy.
We raised the possibility that decreased expression
of TGF-bIIR may inhibit the downstream Smad sig-
naling intermediates of TGF-b ultimately inhibiting the
progression of renal lesions in diabetic mice. To ad-
dress this question, we have attempted to compare the
severity of renal lesions, the expression of phosphory-
lated Smad2/Smad3, and the binding activity of nuclear
1859
1860 Kim et al: TGF-bIIR in diabetic nephropathy
proteins to labeled CAGA sequences in the glomeruli be-
tween HT STZ diabetic mice and wild-type STZ diabetic
animals.
METHODS
Experimental animals
TGF-bIIR+/− (HT) C57BL/6J mice [21] were kindly
donated by Dr. Seong-Jin Kim (Laboratory of Cell Reg-
ulation and Carcinogenesis, National Cancer Institute,
Bethesda, MD, USA). The chimeric mice were analyzed,
and HT mice were bred as described [21]. HT and wild-
type mice were fed standard pellet laboratory chow and
provided with water ad libitium.
Diabetes was induced in weight-matched 8-week-old
HT or wild-type mice by two consecutive daily intraperi-
toneal injections of STZ (200 mg/kg body weight) (Sigma,
St. Louis, MO, USA) dissolved in 10 mmol/L sodium cit-
rate, pH 5.5. Wild-type and HT control mice were injected
with buffer alone. After diabetes was induced, blood glu-
cose concentration was evaluated daily using a freestyle
blood glucose monitoring system to maintain it within
200 to 400 mg/dL by injecting insulin.
The experiment continued for 28 weeks. Urine was col-
lected during a 24-hour period from mice in metabolic
cages on the tenth week of experiment. During collection
mice were allowed free access to water, but food was with-
drawn. Urine protein was quantified using bicinchoninic
acid with bovine serum albumin (BSA) as a standard.
After week 10, however, no more urine collection was
made because the mice did not tolerate the conditions in
metabolic cages sometimes not drinking at all. At the end
of the experiment, the mice were exsanguinated (up to
1 mL blood/mouse) via aortic puncture under ether anes-
thesia and plasma was obtained. Plasma glucose, urea ni-
trogen, and creatinine were measured with commercial
kits on an automated analyzer.
Histology and morphometry
Midline coronal sections of the kidney were fixed
overnight in 4% paraformaldehyde at 4◦C, embedded in
paraffin and stained with periodic acid-Schiff (PAS).
Mean glomerular area was determined on light micro-
scopic sections at a magnification of ×200 by the method
of point-counting as previously described [22, 23]. At least
40 glomeruli were counted for each animal.
To quantitate the volume density (Vv) of the
mesangium, ten glomeruli from each group were ran-
domly assessed. The area of the glomerular tuft (Ag)
was measured on each glomerulus followed by the area
of the mesangium (Am) under oil at ×1000 using point-
counting with a 100-point grid placed on an eyepiece.
Area density (Aa) of the mesangium was estimated as
Aa = Am/Ag. With the assumption that Vv could repre-
sent Aa in this circumstance, Vv of the mesangium was
estimated as Vv = Am/Ag.
Immunohistochemistry
All primary antibodies were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Deparaf-
finized sections were baked in a microwave oven for
5 to 15 minutes. Endogenous peroxidase activity was
quenched with a methanol-H2O2 solution. Sections were
incubated overnight at 4◦C with rabbit anti-TGF-bIIR at
a dilution of 1 in 100. Other sections were incubated with
antiphosphorylated Smad2/Smad3 at a dilution of 1 in
1000 for 1.5 hours at room temperature. The horseradish
peroxidase-conjugated EnVision kit (Dako, Glostrup,
Denmark) was used in the immunnohistochemical re-
action for TGF-bIIR/Smad proteins. Diaminobenzidine
with 3% cobalt was used as the chromogen. The sections
were counterstained with Mayer’s hematoxylin. Control
experiments were performed by omitting the primary an-
tibody or replacing it with the corresponding nonimmune
serum.
Expression patterns of TGF-bIIR and phosphorylated
Smad2/Smad3 in glomeruli were assessed by two pathol-
ogists (H.W.K. and H.S.L.) independently in a blinded
manner. For each glomerulus, a quantitative analysis
for TGF-bIIR and phosphorylated Smad2/Smad3 was
performed. First, the total number of glomerular cells
was counted. Next, the number of glomerular cells that
stained positive for each antibody was counted to obtain
the percentage of glomerular cells that express TGF-bIIR
and Smad proteins.
Generation of digoxigenin (DIG)-labeled
oligonucleotides
The sequence of the double-stranded CAGA
oligonucleotides was 5′-TCG-AGA-GCC-AGA-CAA-
GGA-GCC-AGA-CAA-GGA-GCC-AGA-CAC-3′ and
its complementary strand [10].
DIG-labeled oligonucleotides were generated us-
ing a DIG oligonucleotide tailing kit (Roche Diag-
nostics GmbH, Mannheim, Germany). The labeling
reaction components, including a reaction buffer,
CoCl2, deoxyadenosine triphosphate (dATP), DIG-
labeled deoxyuridine triphosphate (DIG-dUTP) and
terminal transferase were mixed with the oligonu-
cleotides. The mixture was incubated at 37◦C for
15 minutes. The reaction was terminated with a glycogen-
ethylene diamine tetraacetic acid (EDTA) mixture.
Southwestern histochemistry
Southwestern histochemistry was performed as previ-
ously described by Hernandez-Presa, Gomez-Guerrero,
and Egido [24]. Deparaffinized kidney sections were
incubated with levamisole (Sigma) to quench endoge-
nous alkaline phosphatase activity and fixed with 0.2%
paraformaldehyde. Sections were then digested with
pepsin A and were incubated with 0.1 mg/mL DNase 1
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Table 1. Clinical characteristics of experimental mice
Kidney Plasma Plasma urea Plasma Urinary
Body Kidney weight/body glucose nitrogen creatinine proteina
Number weight g weight mg weight mg/g mg/dL mg/dL mg/dL mg/day
Wild-type control 6 25.9 ± 2.6 150 ± 20 5.9 ± 0.3 106 ± 24 32.7 ± 5.5 0.48 ± 0.05 1.1 ± 0.6
Wild-type diabetic mice 10 28.2 ± 1.7 232 ± 42b 8.4 ± 2.1c 451 ± 154b 38.6 ± 9.8 0.60 ± 0.05b 7.3 ± 3.4d
HT control 6 29.2 ± 4.6 180 ± 40 6.2 ± 1.0 122 ± 29 31.3 ± 7.5 0.5 1.3 ± 0.9
HT diabetic mice 10 31.8 ± 1.2 225 ± 34b 7.1 ± 1.2 484 ±186b 30.2 ± 10.7 0.65 ± 0.09b 2.7 ± 1.2b
HT is TGF-b type II receptor gene heterozygous. Data are expressed as mean ± SD.
aData obtained on week 10 of experiment; bP < 0.05 vs. wild-type control or HT control; cP < 0.05 vs. wild-type control; dP < 0.05 vs. all other groups.
in HEPES-BSA. The labeled oligonucleotide probe, di-
luted to 100 pmol/L in HEPES-BSA containing 0.5 lg/mL
poly deoxyinosin-deoxycytosin (Amersham Pharmacia,
Piscataway, NJ, USA) was applied to each slide overnight
at 37◦C. For a competition experiment, sections were
preincubated with a 100-fold molar excess of unlabeled
oligonucleotide for 30 minutes before addition of the la-
beled probe. After incubation in blocking solution, alka-
line phosphatase-labeled anti-DIG antibody was added
overnight at 4◦C. Nitro blue tetrazolium (NBT/BCIP)
(Roche Diagnostics Gmbtt) was added and the slides
were incubated at room temperature for 2 to 6 hours.
Northern blot analysis
The harvested mouse kidney tissues were processed
for RNA isolation according to the acid guanithium
thiocyanate-phenol-chloroform extraction method. Iso-
lated RNA samples were transferred onto nylon filters.
The blotted membranes were incubated with the specific
[32P]-labeled cDNA probes for mouse a1(IV) collagen
and b-actin as we previously described [25]. The filters
were dried and exposed at −70◦C using Agfa film (Agfa-
Gevaert, Hortsel, Belgium). The mRNA levels for a1(IV)
collagen were expressed as a ratio of the optical density
units for a1(IV) collagen to b-actin.
Statistics
Results were presented as mean ± SD. The significance
of differences among three or four groups was assessed
using two-way analysis of variance (ANOVA). Results
between two groups were analyzed by Wilcoxon’s rank
sum test. A P value of less than 0.05 was considered
significant.
RESULTS
Clinical characteristics
The characteristics of the experimental mice are pre-
sented in Table 1. Both the wild-type diabetic and the HT
diabetic mice were hyperglycemic by the end of the ex-
perimental period and showed significantly greater kid-
ney weights as compared with the HT and the wild-type
controls. The body weights between the four groups of
mice were not significantly different. However, average
kidney-to-body weight ratios were significantly higher in
the wild-type diabetic than the wild-type controls because
the wild-type diabetic mice showed much greater kidney
weights than the wild-type controls. Plasma creatinine
levels in wild-type diabetic and HT diabetic mice were
significantly higher than those of control animals. Plasma
urea nitrogen levels in wild-type diabetic mice tended to
be higher than those of other groups of animals. How-
ever, the difference was not statistically significant. At
the week 10 of the study, the amounts of proteinuria in
the wild-type diabetic mice were significantly larger than
those of HT diabetic and control mice.
Pathology and morphometry
Wild-type and HT control mice showed segmen-
tal mesangial cell proliferation (Fig. 1A and B). The
glomerular ECM accumulation in the mesangium was
most prominent in the wild-type diabetic mice occasion-
ally forming nodular glomerulosclerosis (Fig. 1C). In the
HT diabetic mice, a mild increase in the mesangial ma-
trix was focally observed with slight mesangial cell pro-
liferation. Nodular glomerulosclerosis, however, was not
present at all (Fig. 1D).
The mean glomerular area was significantly increased
(P < 0.05) in the wild-type diabetic mice (6636 ±
508 lm2) compared with the HT diabetic mice (4889 ±
593 lm2), HT control (4845 ± 432 lm2), or wild-type con-
trol (3934 ± 151 lm2) mice. Although the mean glomeru-
lar area in the HT diabetic mice or HT control tended to
be larger than that in the wild-type control, the difference
was not statistically significant (Table 2).
Mesangial volume density [Vv (mesangium/glom)] in
the wild-type diabetic mice was significantly increased
(P < 0.05) compared with the HT diabetic, HT control,
or wild-type control mice. Increase in the matrix mainly
contributed to mesangial expansion in the wild-type di-
abetic mice. Vv (mesangium/glom) was not significantly
different between the HT diabetic and HT control and
wild-type control animals (Table 2).
Immunohistochemistry
TGF-bIIR. No staining for TGF-bIIR was observed
in the glomeruli of the wild-type and HT control mice
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Fig. 1. Light microscopic views. Shown are glomeruli from wild-type control mouse (A), transforming growth factor-b (TGF-b) type II receptor
(TGF-bIIR) gene heterozygous (TGF-bIIR+/−) (HT) control mouse (B), wild-type diabetic mouse (C), and HT diabetic mouse (D) at 28 weeks
of experiment. Periodic acid-Schiff (PAS) stain, ×400.
Table 2. Pathologic characteristics of experimental mice
Immunohistochemistry Southwestern histochemistry
Morphometry TGF-bIIR p-Smad CAGA boxes
Glomerular area Vv (mesangium/ Percent-positive No. of DNA-binding
N lm2 glomerulus) lm3/lm3 glomerular cells cells/glomerulus
Wild-type control 6 3934 ± 151 0.14 ± 0.02 0 0 2.8 ± 0.1
Wild-type diabetic mice 8 6636 ± 508a 0.27 ± 0.09a 21 ± 10a 68 ± 13a 16.5 ± 0.1a
HT control 6 4845 ± 432 0.15 ± 0.06 0 0 4.1 ± 0.1
HT diabetic mice 8 4889 ± 593 0.15 ± 0.02 0 11 ± 8 7.4 ± 0.5
Abbreviations are: Vv, volume density; TGF-bIIR, TGF-b type II receptor; p-Smad, phosphorylated Smad2/Smad3; HT, TGF-b type II receptor gene heterozygous.
aP < 0.05 vs. HT diabetic mice, wild-type control, or HT control.
Data are expressed as mean ± SD.
(Fig. 2A and B) and HT diabetic mice (Fig. 2D). In
the wild-type diabetic mice, TGF-bIIR immunoreactiv-
ity was observed in several glomerular cells (Fig. 2C)
(Table 2).
Phosphorylated Smad2/Smad3. In the wild-type
and HT controls, immunostaining for phosphorylated
Smad2/Smad3 was almost negligible (Fig. 2E and F). In
the wild-type diabetic mice, glomerular cells frequently
exhibited positive nuclear staining for phosphorylated
Smad2/Smad3 (Fig. 2G) (Table 2). Tubular epithelial cells
also frequently showed positive staining for phosphory-
lated Smads. In the HT diabetic mice, however, several
glomerular or tubular cells exhibited positive staining for
phosphorylated Smad2/Smad3 (Fig. 2H) (Table 2).
Southwestern histochemistry
In wild-type control (Fig. 3A) and HT control (Fig. 3B),
binding activity of nuclear proteins to a DIG-labeled
CAGA sequence was almost negligible. An increased
amount of nuclear proteins that bound to a DIG-labeled
CAGA sequence was evident in the glomerular and tubu-
lar cells of a wild-type diabetic mouse (Fig. 3C) com-
pared with an HT diabetic mouse (Fig. 3D) (Table 2).
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Fig. 2. Immunoperoxidase staining. Shown are transforming growth
factor-b (TGF-b) type II receptor (TGF-bIIR) (A to D) and phos-
phorylated Smad2/Smad3 (E to H) in the glomeruli of the wild-type
controls (A and E), HT controls (B and F), wild-type diabetic mice (C
and G), and HT diabetic mice (D and H). In wild-type (A and E) and
HT (B and F) controls, there is no staining for TGF-bIIR (A and B)
and phosphorylated Smad2/Smad3 (E and F). In the wild-type diabetic
mice, glomerular cells exhibit positive staining for TGF-bIIR (arrows)
(C) and phosphorylated Smad2/Smad3 (G). In the HT diabetic mice,
there is no staining for TGF-bIIR (D), but a few glomerular cells exhibit
positive staining for phosphorylated Smad2/Smad3 (H).
Incubation with a 100-fold excess of unlabeled oligonu-
cleotide probes in wild-type diabetic mice resulted in neg-
ative staining of the glomeruli and tubules, demonstrating
the specificity of CAGA sequence binding (Fig. 3E).
Northern blot analysis
In the kidney tissue of wild-type diabetic mice, a1(IV)
collagen transcripts were significantly increased to 1.8-
fold higher than the HT diabetic mice or wild-type or HT
controls (Fig. 4).
DISCUSSION
This study demonstrates that the severity of glomeru-
lar lesions, renal a1(IV) collagen mRNA expression, and
Fig. 3. Nuclear binding activity to CAGA sequence by Southwestern
histochemistry. The glomeruli of the wild-type control (A), HT control
(B), wild-type diabetic mouse (C), and HT diabetic mouse (D). An
increased amount of nuclear proteins that bind to a labeled CAGA se-
quence is evident in the glomerular cells of wild-type diabetic mouse
(C) compared with wild-type control (A), HT control (B), and HT dia-
betic mouse (D). For competition experiments, sections from wild-type
diabetic mice were preincubated with a 100-fold excess of unlabeled
oligonucleotide probe before addition of labeled probe (E).
phosphorylated Smad2/Smad3 expression and the bind-
ing activity of nuclear proteins to Smad binding sites in
the glomerular cells are significantly decreased in HT di-
abetic mice as compared with wild-type diabetic animals.
These results suggest that TGF-bIIR plays an important
role in the progression of diabetic nephropathy.
We found that nuclear staining for phosphorylated
Smad2/Smad3 was frequently positive in the glomerular
cells in the wild-type diabetic mice, whereas it was almost
negligible in the HT diabetic mice. Although diffuse cy-
toplasmic and nuclear staining for Smad3 has been de-
scribed in the glomeruli of db/db mice [19], this is the first
study demonstrating that phosphorylated Smads translo-
cate into the nuclei of the glomerular cells in the STZ
diabetic mice. As expected, our wild-type diabetic mice,
but not the HT diabetic animals, showed immunoreac-
tivity for TGF-bIIR in some glomerular cells. TGF-bIIR
expression is increased in the glomeruli of experimen-
tal models of diabetes [16–19] and in the lesions of focal
segmental glomerulosclerosis [26]. Increased TGF-bIIR
expression in our wild-type diabetic mice may allow
the glomerular cells to respond actively to high blood
glucose-induced TGF-b , leading to the activation of the
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Fig. 4. Northern blot analysis of a1(IV) collagen mRNA in the kidney
tissue. Shown are wild-type control (WT-CON) (lane 1), wild-type dia-
betic mice (WT-DM) (lane 2), HT control (HT-CON) (lane 3), and HT
diabetic mice (HT-DM) (lane 4). The blots were hybridized with [32P]-
labeled cDNA for a1(IV) collagen (A) and b-actin (B). (C) Quantita-
tive expression of a1(IV) collagen mRNA abundance after correcting
for the b-actin signal. The a1(IV) collagen mRNA levels of experimen-
tal mice are expressed as percent increases compared with the mRNA
levels of wild-type controls. Values are means ± SD. ∗P < 0.05 vs. HT
diabetic mice, wild-type control, or HT control.
TGF-b type I receptor and nuclear accumulation of phos-
phorylated Smads. In contrast, glomerular cells with de-
creased TGF-bIIR expression in the HT diabetic mice
may not respond well to diabetes-induced TGF-b , thus
inhibiting the TGF-b–induced nuclear accumulation of
phosphorylated Smad2/Smad3.
Smad2 cannot bind directly to DNA as compared to
Smad3 [27, 28]. Smad3 deficiency attenuates bleomycin-
induced pulmonary fibrosis in mice [29]. In cultured
mesangial cells, Smad3 overexpression increases fi-
bronectin promoter activity [30], and Smad3 has been
found to be involved in TGF-b–induced stimulation of
the a2(I) collagen [13]. These reports suggest that Smad3
plays a key role in intracellular Smad signaling and ECM
accumulation.
Smad3 and/or Smad4 can activate transcription from
TGF-b responsive promoters, such as PAI-1, a1(I) and
a2(I) collagen, fibronectin and TGF-b itself [10–13, 31–
34], through direct binding to a discrete DNA sequence
[9, 10]. CAGA boxes themselves might be sufficient
to mediate TGF-b transcriptional effects [10], although
Smads must cooperate with other transcription factors to
effect the transcription of a target gene [13, 31, 35].
We observed an increased localization of DIG-labeled
CAGA sequence probe to the nuclei of glomerular cells
in the wild-type diabetic mice compared with the HT
diabetic animals. In support of our Southwestern histo-
chemistry results, increased binding of nuclear proteins
to labeled SBE oligonucleotides has been described in
diabetic mice [19, 30]. Altogether, decreased TGF-bIIR
expression in HT diabetic mice compared with wild-type
diabetic mice can reduce Smad/DNA interactions and
ECM promoter activation in glomerular cells, thus pre-
venting the progression of diabetic nephropathy.
The changes of glomerular hypertrophy and mesan-
gial expansion observed in our wild-type diabetic mice
were similar to those of previous reports in rats that had
been diabetic for one to 8 months [36]. As the mesangial
matrix expands, it impinges on glomerular capillaries, re-
ducing the filtration surface and narrowing the capillary
lumen. In support of our notion that decreased TGF-
bIIR expression can reduce ECM promoter activation
via decreased Smad/DNA interactions, mean glomerular
area and mesangial volume density in our HT diabetic
mice were significantly reduced as compared with the
wild-type diabetic animals. Furthermore, this reduction
in the HT diabetic mice was accompanied by a decrease
in the renal overexpression of a1(IV) collagen mRNA,
assessed by Northern blot. Thus, decreased expression of
TGF-bIIR in the HT diabetic mice could ameliorate re-
nal overproduction of ECM proteins, mesangial matrix
accumulation, and subsequent glomerular hypertrophy
by inhibiting both the activation of TGF-b type I recep-
tor, and intracellular Smad signaling to the nucleus.
Neutralizing antibodies against TGF-b1 prevents the
accumulation of ECM in nephritic or diabetic rodents
[37–39]. SB-431542 [40], an inhibitior of the TGF-b type I
receptor, inhibits TGF-b1–induced phosphorylation of
Smad3, nuclear Smad3 localization, and ECM production
[41]. In this regard, an attempt to identify the TGF-bIIR
inhibitor merits further attention.
CONCLUSION
Our results suggest that decreased expression of TGF-
bIIR in the HT diabetic mice can inhibit the progression
of renal injury by inhibiting the downstream Smad sig-
naling pathway and subsequent ECM gene expression.
Thus, TGF-bIIR appears to play an important role in the
progression of diabetic nephropathy by mediating intra-
cellular Smad signaling.
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